Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
van der Sluis IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, Bierings M, van den Bos C, de Haas V, Hoogerbrugge PM, Tissing WJE, Veening MA, Pieters R. van der Sluis IM, et al. Among authors: hoogerbrugge pm. J Clin Oncol. 2024 May 10;42(14):1676-1686. doi: 10.1200/JCO.23.01797. Epub 2024 Feb 2. J Clin Oncol. 2024. PMID: 38306592 Free PMC article. Clinical Trial.
Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V, Van Dongen J. Pieters R, et al. J Clin Oncol. 2016 Aug 1;34(22):2591-601. doi: 10.1200/JCO.2015.64.6364. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269950
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups.
Pieters R, de Groot-Kruseman H, Fiocco M, Verwer F, Van Overveld M, Sonneveld E, van der Velden V, Beverloo HB, Bierings M, Dors N, de Haas V, Hoogerbrugge P, Van der Sluis I, Tissing W, Veening M, Boer J, Den Boer M. Pieters R, et al. J Clin Oncol. 2023 Sep 1;41(25):4130-4142. doi: 10.1200/JCO.22.02705. Epub 2023 Jul 17. J Clin Oncol. 2023. PMID: 37459571
Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia.
den Hoed MA, Pluijm SM, te Winkel ML, de Groot-Kruseman HA, Fiocco M, Hoogerbrugge P, Leeuw JA, Bruin MC, van der Sluis IM, Bresters D, Lequin MH, Roos JC, Veerman AJ, Pieters R, van den Heuvel-Eibrink MM. den Hoed MA, et al. Haematologica. 2015 Dec;100(12):1564-70. doi: 10.3324/haematol.2015.125583. Epub 2015 Sep 24. Haematologica. 2015. PMID: 26405155 Free PMC article. Clinical Trial.
Outcome after first relapse in children with acute lymphoblastic leukemia: a report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol.
van den Berg H, de Groot-Kruseman HA, Damen-Korbijn CM, de Bont ES, Schouten-van Meeteren AY, Hoogerbrugge PM. van den Berg H, et al. Among authors: hoogerbrugge pm. Pediatr Blood Cancer. 2011 Aug;57(2):210-6. doi: 10.1002/pbc.22946. Epub 2011 Feb 18. Pediatr Blood Cancer. 2011. PMID: 21337680 Clinical Trial.
The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.
den Hoed MA, Pluijm SM, de Groot-Kruseman HA, te Winkel ML, Fiocco M, van den Akker EL, Hoogerbrugge P, van den Berg H, Leeuw JA, Bruin MC, Bresters D, Veerman AJ, Pieters R, van den Heuvel-Eibrink MM. den Hoed MA, et al. Haematologica. 2015 Jan;100(1):62-9. doi: 10.3324/haematol.2014.110668. Epub 2014 Oct 10. Haematologica. 2015. PMID: 25304613 Free PMC article.
Upfront Treatment Influences the Composition of Genetic Alterations in Relapsed Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
Yu J, Waanders E, van Reijmersdal SV, Antić Ž, van Bosbeek CM, Sonneveld E, de Groot H, Fiocco M, Geurts van Kessel A, van Leeuwen FN, Pieters R, Hoogerbrugge PM, Kuiper RP. Yu J, et al. Among authors: hoogerbrugge pm. Hemasphere. 2020 Jan 22;4(1):e318. doi: 10.1097/HS9.0000000000000318. eCollection 2020 Feb. Hemasphere. 2020. PMID: 32072138 Free PMC article.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. van der Veer A, et al. Among authors: hoogerbrugge pm. Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23. Blood. 2013. PMID: 23974192 Free PMC article.
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.
Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML. Boer JM, et al. Leukemia. 2016 Jan;30(1):32-8. doi: 10.1038/leu.2015.199. Epub 2015 Jul 23. Leukemia. 2016. PMID: 26202931
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia.
Dekker L, Calkoen FG, Jiang Y, Blok H, Veldkamp SR, De Koning C, Spoon M, Admiraal R, Hoogerbrugge P, Vormoor B, Vormoor HJ, Visscher H, Bierings M, Van Der Vlugt M, Van Tinteren H, Nijstad AL, Huitema ADR, Van Der Elst KCM, Pieters R, Lindemans CA, Nierkens S. Dekker L, et al. Blood Adv. 2022 Apr 12;6(7):1969-1976. doi: 10.1182/bloodadvances.2021006700. Blood Adv. 2022. PMID: 35134115 Free PMC article.
159 results